טוען...
Vaccines for the prevention against the threat of MERS-CoV
First identified in 2012, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is listed as a new Category C Priority Pathogen. While the high mortality of MERS-CoV infection is further intensified by potential human-to-human transmissibility, no MERS vaccines are available for human use....
שמור ב:
| הוצא לאור ב: | Expert Rev Vaccines |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5097835/ https://ncbi.nlm.nih.gov/pubmed/26985862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14760584.2016.1167603 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|